US Market Stock Movers On FDA Decision (EDAP, MYL, BPAX, LIFE, MRK)

EDAP TMS SA (Nasdaq: EDAP) today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

Subscribe to daily free stock newsletter by visiting:  http://www.PennyStockPickReport.com

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market Methamphetamine Hydrochloride Tablets USP, 5 mg, based on an agreement with licensing partner Coastal Pharmaceuticals.

BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante’s 2A/Furin technology in the expression of antibodies.

Life Technologies Corporation (Nasdaq: LIFE) today debuted the life science industry’s first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols.

Nycomed and Merck & Co., Inc. (NYSE: MRK) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD).

About http://www.pennystockpickreport.com/

Penny Stock Pick Report offers stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks, most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.